Steris

STERIS to Host a Conference Call for Fiscal 2024 Fourth Quarter and Full Year Financial Results on May 9, 2024

Retrieved on: 
Wednesday, April 24, 2024
Steris, STE

DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year financial results at 9:00 a.m.

Key Points: 
  • DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year financial results at 9:00 a.m.
  • ET on May 9, 2024.
  • The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
  • A press release detailing financial results will be issued after the U.S. market closes on May 8, 2024.

STERIS to Sell Dental Segment to an affiliate of Peak Rock Capital

Retrieved on: 
Thursday, April 11, 2024
Medtech, Sale, Customer, Steris, Dental, Guggenheim Partners, STE, Acquisition, Transaction

The Transaction terms also include the opportunity for STERIS to receive an additional earnout of up to $12.5 million, subject to the achievement of certain revenue targets of the Dental segment in fiscal 2025.

Key Points: 
  • The Transaction terms also include the opportunity for STERIS to receive an additional earnout of up to $12.5 million, subject to the achievement of certain revenue targets of the Dental segment in fiscal 2025.
  • The Dental segment reported revenue of $407 million and contributed segment operating income of $86 million in the trailing twelve-month period ended December 31, 2023.
  • “Since acquiring our Dental segment through the Cantel acquisition, we have focused on deploying lean manufacturing methods to drive operating efficiencies.
  • The Dental segment will be reported as discontinued operations for the fourth quarter and full year of fiscal 2024.

Healthcare Analytical Testing Services Market Worth $12.6 billion | MarketsandMarkets™

Retrieved on: 
Wednesday, April 10, 2024
Merck Group, Pulse, Investment, Steris, ICON PLC, Parexel, Health care, Research, Sartorius AG, Wuxi, Intertek, Legal Entity Identifier, Labcorp, Region, Acquisition, Charles River Laboratories, SGS, Eurofins Scientific, INC, Market development

This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.

Key Points: 
  • This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.
  • This strategic acquisition strengthens SGS's presence in key market segments and enhances its ability to deliver comprehensive services to clients worldwide.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=108923833
    Healthcare Analytical Testing Services Market - Key Benefits of Buying the Report:
    This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare analytical testing services market
    Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare analytical testing services market like Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK) among others.

Healthcare Analytical Testing Services Market Worth $12.6 billion | MarketsandMarkets™

Retrieved on: 
Wednesday, April 10, 2024
Merck Group, Pulse, Investment, Steris, ICON PLC, Parexel, Health care, Research, Sartorius AG, Wuxi, Intertek, Legal Entity Identifier, Labcorp, Region, Acquisition, Charles River Laboratories, SGS, Eurofins Scientific, INC, Market development

This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.

Key Points: 
  • This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.
  • This strategic acquisition strengthens SGS's presence in key market segments and enhances its ability to deliver comprehensive services to clients worldwide.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=108923833
    Healthcare Analytical Testing Services Market - Key Benefits of Buying the Report:
    This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare analytical testing services market
    Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare analytical testing services market like Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK) among others.

STERIS Announces Financial Results for Fiscal 2024 Third Quarter

Retrieved on: 
Wednesday, February 7, 2024
Customer, STE, Steris, Growth, Public expenditure, Video game

Third quarter revenue increases 15% as reported; 10% constant currency organic

Key Points: 
  • Third quarter revenue increases 15% as reported; 10% constant currency organic
    As reported diluted earnings per share increased to $1.42; adjusted earnings per share increased to $2.22
    DUBLIN, IRELAND, Feb. 07, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 third quarter ended December 31, 2023.
  • Constant currency organic revenue (see Non-GAAP Financial Measures) increased 10% for the third quarter of fiscal 2024 as compared to the third quarter of fiscal 2023.
  • Healthcare revenue as reported grew 19% in the quarter to $916.2 million compared with $769.1 million in the third quarter of fiscal 2023.
  • Reflecting lower volume, operating income was $18.3 million in the third quarter of fiscal 2024 compared with $20.3 million in the prior year’s third quarter.

STERIS Announces Dividend of $0.52 per share

Retrieved on: 
Tuesday, January 30, 2024
Pillar, MLI, COVID-19, Growth, Congress, Pressure, Legislation, Literature, Annual report, FDA, Marketing, CAMT, Acquisition, IRA, TCJA, Risk, Health, EPA, STE, Steris, Insurance, Income tax, Accounting

DUBLIN, IRELAND , Jan. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share.

Key Points: 
  • DUBLIN, IRELAND , Jan. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share.
  • The dividend is payable on March 22, 2024, to shareholders of record at the close of business on February 23, 2024.
  • Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com .
  • STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention.

STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024

Retrieved on: 
Tuesday, January 23, 2024
STE, Steris

DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 third quarter financial results at 9:00 a.m.

Key Points: 
  • DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 third quarter financial results at 9:00 a.m.
  • The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
  • A press release detailing financial results will be issued after the U.S. market closes on February 7, 2024.
  • For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m.

STERIS Announces Financial Results for Fiscal 2024 Second Quarter

Retrieved on: 
Tuesday, November 7, 2023
BD, Steris, Growth, Customer, NYSE, Health care, Dental, STE, AST, Video game

Constant currency organic revenue (see Non-GAAP Financial Measures) increased 8% for the second quarter of fiscal 2024 as compared to the second quarter of fiscal 2023.

Key Points: 
  • Constant currency organic revenue (see Non-GAAP Financial Measures) increased 8% for the second quarter of fiscal 2024 as compared to the second quarter of fiscal 2023.
  • Adjusted net income (see Non-GAAP Financial Measures) for the second quarter of fiscal 2024 was $202.2 million or $2.03 per diluted share, compared with the previous year’s second quarter of $199.6 million or $1.99 per diluted share.
  • Dental second quarter revenue as reported declined 5% to $104.2 million compared with $109.6 million in the second quarter of fiscal 2023.
  • Reflecting lower volume, operating income was $24.5 million in the second quarter of fiscal 2024 compared with $28.1 million in the prior year’s second quarter.

STERIS Announces Dividend of $0.52 per share

Retrieved on: 
Tuesday, October 31, 2023
Pillar, FDA, Insurance, NYSE, American Bar Association Model Rules of Professional Conduct, Literature, Pressure, IRA, CAMT, Congress, Legislation, Acquisition, Health, TCJA, EPA, Growth, Risk, COVID-19, MLI, Income tax, Marketing, Steris, Annual report, Accounting, STE, Cantel Medical Corporation, Brexit, EU

DUBLIN, IRELAND, Oct. 31, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share.

Key Points: 
  • DUBLIN, IRELAND, Oct. 31, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share.
  • The dividend is payable on December 21, 2023, to shareholders of record at the close of business on November 21, 2023.
  • STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention.
  • WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services around the globe.

FDA Roundup: October 31, 2023

Retrieved on: 
Tuesday, October 31, 2023
Cream, Ice cream, FDA, Steris, Food, Ethylene oxide, Vaccine, Listeria monocytogenes, Cisplatin, Human services, Infection, News, Medical device, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMA, HIV disease progression rates, Cosmetics, NPC, Soft serve, Multimedia, Dietary supplement, Environment, Nasopharyngeal carcinoma, Disease, Radiation, EO, Sterilization, Public, House, Woman, Safety, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Heated tobacco product, China Biologic Products, Animal, Essure

The FDA remains committed to collecting and providing updates on the long-term safety and effectiveness information about Essure, a permanently implanted birth control device for women.

Key Points: 
  • The FDA remains committed to collecting and providing updates on the long-term safety and effectiveness information about Essure, a permanently implanted birth control device for women.
  • Although Essure has not been available for implantation in the United States since December 2019, the FDA continues to monitor the product's safety through an FDA-required postmarket surveillance ("522") study and other activities.
  • The master file was submitted by Steris Corporation, Sterilization for Medical Devices | FDA .
  • The FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.